NCT02226276View on ClinicalTrials.gov

Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer

NAActive, not recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

January 7, 2015

Primary Completion Date

December 7, 2021

Study Completion Date

October 30, 2025

Conditions
Bone MetastasesHER2-positive Breast CancerLiver MetastasesLung MetastasesRecurrent Breast CancerSoft Tissue MetastasesStage IV Breast Cancer
Interventions
RADIATION

fludeoxyglucose F 18

Undergo fludeoxyglucose F 18 PET/CT

PROCEDURE

positron emission tomography

Undergo fludeoxyglucose F 18 PET/CT

PROCEDURE

computed tomography

Undergo fludeoxyglucose F 18 PET/CT

BIOLOGICAL

trastuzumab

Given IV

RADIATION

copper Cu 64-DOTA-trastuzumab

Given IV

PROCEDURE

positron emission tomography

Undergo copper Cu-DOTA-trastuzumab PET

BIOLOGICAL

ado-trastuzumab emtansine

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER

NCT02226276 - Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer | Biotech Hunter | Biotech Hunter